Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Smith & Nephew plc (GB:SN)
LSE:SN
Holding GB:SN?
Track your performance easily
SN Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range887.00p - 1,245.26p
Previous Close1,176p
Volume159.31K
Average Volume (3M)2.29M
Market Cap
£10.25B
Enterprise Value12.37B
Total Cash (Recent Filing)$302.00M
Total Debt (Recent Filing)$3.08B
Price to Earnings (P/E)42.9
Beta0.82
Next Earnings
Feb 25, 2025EPS Estimate
£0.37Next Dividend Ex-Date
Oct 03, 2024Dividend Yield2.55%
Share Statistics
EPS (TTM)0.28
Shares Outstanding874,372,747
10 Day Avg. Volume2,300,551
30 Day Avg. Volume2,287,005
Standard Deviation0.07
R-Squared0.28
Alpha-0.00798
Financial Highlights & Ratios
Price to Book (P/B)197.65
Price to Sales (P/S)2.42
Price to Cash Flow (P/CF)28.70
P/FCF Ratio50.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.24
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
1,346.44pPrice Target Upside15.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Smith & Nephew News
Options Prices
Currently, No data available
---
Ownership Overview
0.57% Insiders
12.64% Mutual Funds
8.69% Other Institutional Investors
78.10% Public Companies and
Individual Investors
SN FAQ
What was Smith & Nephew plc’s price range in the past 12 months?
Smith & Nephew plc lowest share price was 887.00p and its highest was 1245.26p in the past 12 months.
What is Smith & Nephew plc’s market cap?
Currently, no data Available
When is Smith & Nephew plc’s upcoming earnings report date?
Smith & Nephew plc’s upcoming earnings report date is Feb 25, 2025 which is in 158 days.
How were Smith & Nephew plc’s earnings last quarter?
Smith & Nephew plc released its earnings results on Aug 01, 2024. The company reported 0.288p earnings per share for the quarter, missing the consensus estimate of 0.299p by -0.011p.
Is Smith & Nephew plc overvalued?
According to Wall Street analysts Smith & Nephew plc’s price is currently Undervalued.
Does Smith & Nephew plc pay dividends?
Smith & Nephew plc pays a Semiannually dividend of 11.26p which represents an annual dividend yield of 2.55%. See more information on Smith & Nephew plc dividends here
What is Smith & Nephew plc’s EPS estimate?
Smith & Nephew plc’s EPS estimate is £0.37.
How many shares outstanding does Smith & Nephew plc have?
Smith & Nephew plc has 874,372,740 shares outstanding.
What happened to Smith & Nephew plc’s price movement after its last earnings report?
Smith & Nephew plc reported an EPS of 0.288p in its last earnings report, missing expectations of 0.299p. Following the earnings report the stock price went up 6.768%.
Which hedge fund is a major shareholder of Smith & Nephew plc?
Currently, no hedge funds are holding shares in GB:SN
---
Smith & Nephew Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
1,346.44p (15.65% Upside)
1,346.44p (15.65% Upside)
Insider Transactions
Sold Shares
Worth £131.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.83%
12-Months-Change
Fundamentals
Return on Equity
5.87%
Trailing 12-Months
Asset Growth
7.70%
Trailing 12-Months
Company Description
Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and ENT technologies, and wound-care solutions. Slightly more than 40% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 27% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
---
SN Stock 12 Month Forecast
Average Price Target
1,346.44p
▲(15.65% Upside)
Technical Analysis
Advanced Medical Solutions
―
GlaxoSmithKline
―
Hikma Pharmaceuticals
―
Belluscura PLC
―
Best Analysts Covering SN
1 Year
1 Year Success Rate
4/5 ratings generated profit
1 Year Average Return
+12.10%
reiterated a buy rating 2 months ago
Copying David Adlington's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +12.10% per trade.
---